Is It Time To Reassess Travere Therapeutics (TVTX) After Its Recent Price Surge [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
If you are wondering whether Travere Therapeutics at around US$38.78 is offering value or asking too much, this breakdown is designed to help you make sense of the current price. The stock has been volatile recently, with a 44.5% return over the last 30 days, a 144.2% return over 1 year, and a 1.9% decline year to date. Recent news flow around Travere Therapeutics has focused on its position in the biotech space and investor reactions to company specific updates, which helps explain some of the sharp price moves. These headlines have kept attention on execution risks and potential upside scenarios, giving extra weight to how the current price compares with underlying fundamentals. On Simply Wall St's 6 point valuation checklist, Travere Therapeutics scores 4 out of 6 . The sections that follow will compare different valuation approaches before circling back to a more rounded way to think about what the stock could be worth. Travere Therapeutics delivered 144.2% returns over t
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Purespring announces publication of notable study highlighting an under recognised genetic driver of adult-onset FSGS, in particular in US and UK populations [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics to Report First Quarter 2026 Financial ResultsBusiness Wire
- Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now? [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics (TVTX) had its "buy" rating reaffirmed by Guggenheim.MarketBeat
- Travere Therapeutics: Still Undervalued Post FSGS Approval [Seeking Alpha]Seeking Alpha
TVTX
Earnings
- 2/19/26 - Beat
TVTX
Sec Filings
- 4/23/26 - Form 4
- 4/22/26 - Form 144
- 4/16/26 - Form 4
- TVTX's page on the SEC website